Abstract | BACKGROUND: DESIGN AND METHODS: We analyzed the outcome of 2612 patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation between 2000 and 2005 and reported to the European Blood and Marrow Transplantation registry. Four hundred and sixty-three patients (18%) were > or =60 years old at the time of the transplant (median, 63 years). When compared to 2149 patients <60 years old at the time of transplantation, the elderly patients had more frequently received at least two treatment lines (76% vs. 57%, p<0.001), were less commonly in first complete remission at the time of transplantation (23 % vs. 30 %, p=0.005) and received their transplants later after diagnosis (median time 14 months vs.7.5 months, p<0.001). RESULTS: Non-relapse mortality was higher in elderly patients at 100 days (4.4 % vs. 2.8 %), at 1 year (8.7% vs. 4.7%) and at 3 years (10.8% vs. 6.5%) (p=0.002). With a median follow-up of 12 months for the surviving patients for the elderly group and 15 months for the younger group, the risk of relapse was 38% and 32%, respectively (p=0.006).The progression-free survival was 51% and 62%, respectively, at 3 years (p<0.001). The overall survival rate was 60% vs. 70%, respectively, at 3 years (p<0.001). CONCLUSIONS:
|
Authors | Esa Jantunen, Carmen Canals, Alessandro Rambaldi, Gert Ossenkoppele, Bernardino Allione, Didier Blaise, Eulogio Conde, Hervè Tilly, Gordon Cook, Fiona Clark, Andrea Gallamini, Andrew Haynes, Nicolas Mounier, Peter Dreger, Michael Pfreundschuh, Anna Sureda, EBMT Lymphoma Working Party |
Journal | Haematologica
(Haematologica)
Vol. 93
Issue 12
Pg. 1837-42
(Dec 2008)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 18838474
(Publication Type: Journal Article)
|
Topics |
- Age Factors
- Aged
- Aged, 80 and over
- Europe
(epidemiology)
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, Large B-Cell, Diffuse
(mortality, therapy)
- Middle Aged
- Registries
- Survival Analysis
- Transplantation, Autologous
- Treatment Outcome
|